The Centralised Procedure for Veterinary Medicines: Mandatory and Optional Scope

Under Regulation (EU) 2019/6, choosing the route to market is not always a free choice. Article 42 lists the products that must go through the centralised procedure, and getting that classification wrong at the outset can cost months.

What a centralised authorisation gives you

A centralised marketing authorisation is valid throughout the Union. The application is submitted to the European Medicines Agency rather than to a national authority, and the scientific evaluation is carried out at EU level. For products with a genuine pan-European market, one dossier and one decision can replace a sequence of national or recognition procedures.

Products for which the route is mandatory

Article 42(2) requires the centralised procedure for the following categories:

  • biotechnological products, including those made by recombinant DNA technology, controlled gene expression or hybridoma and monoclonal antibody methods;
  • performance enhancers intended mainly to promote growth or increase yield in treated animals;
  • products containing a new active substance, meaning one not authorised as a veterinary medicinal product in the Union when the application is submitted;
  • biological products containing or consisting of engineered allogeneic tissues or cells;
  • novel therapy products.

The last two categories do not apply to products made exclusively of blood components.

The optional route

Article 42(4) allows a product outside the mandatory list to receive a centralised authorisation where no other marketing authorisation has been granted for it in the Union. This can suit a first-in-class product that is not strictly captured by the mandatory scope but is intended for several Member States from day one.

Points to settle early

  • Whether the active substance is genuinely new for veterinary use in the Union, or already present in an authorised veterinary product. Human-only authorisation does not make it “authorised” for this purpose, so confirm the position against the Union product database.
  • Whether the dossier meets Annex II requirements and the application content set out in Article 8, including the summary of the pharmacovigilance system master file.
  • Language, labelling and package leaflet planning for every Member State where you intend to launch.
  • For food-producing species, the status of the active substance under the maximum residue limit framework of Regulation (EC) No 470/2009.

Common mistakes to avoid

Applicants most often stumble in three places. First, they assume the route can be chosen late, when in fact the scope question determines the dossier format, the committee that evaluates it and the labelling workload. Second, they treat “new active substance” as a matter of internal novelty rather than of authorisation status in the Union. Third, they plan launch dates around the evaluation alone and forget translation, packaging and artwork lead times for every target market.

A short written route-selection memo, agreed internally before development is finalised, avoids most of these problems. It should record the Article 42 analysis, the alternatives considered and the reasons for the decision, so that it can be revisited if the product profile changes.

How PQRA helps

PQRA helps veterinary marketing authorisation applicants test their product against the Article 42 criteria, compare the centralised route with decentralised, mutual recognition and national options, and plan the dossier, pre-submission interactions and labelling workstreams accordingly.

Contact PQRA to discuss your route to market under Regulation (EU) 2019/6.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *